{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:55:38Z","timestamp":1790963738737,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T00:00:00Z","timestamp":1470268800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Newcastle upon Tyne"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s11934-016-0625-z","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T07:26:21Z","timestamp":1470295581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["High-Risk Non-Muscle-Invasive Bladder Cancer\u2014Therapy Options During Intravesical BCG\u00a0Shortage"],"prefix":"10.1007","volume":"17","author":[{"given":"Rajan","family":"Veeratterapillay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Persad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,4]]},"reference":[{"issue":"2","key":"625_CR1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234\u201341.","journal-title":"Eur Urol"},{"issue":"1","key":"625_CR2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eururo.2013.10.001","volume":"66","author":"S Chavan","year":"2014","unstructured":"Chavan S, Bray F, Lorter-Tieulent J, et al. International variations in bladder cancer incidence and mortality. Eur Urol. 2014;66(1):59\u201373.","journal-title":"Eur Urol"},{"key":"625_CR3","unstructured":"Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumours. UICC International Union Against Cancer. 7th edn. Hoboken, NJ: Wiley-Blackwell; 2009. pp. 262-265."},{"issue":"5","key":"625_CR4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1309\/AJCP12MRVVHTCKEJ","volume":"133","author":"CC Pan","year":"2010","unstructured":"Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO\/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinic pathologic study of 1,515 cases. Am J Clin Pathol. 2010;133(5):788\u201395.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"625_CR5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta, T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466\u20135.","journal-title":"Eur Urol"},{"issue":"2","key":"625_CR6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"P-U Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m P-U, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the longterm outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247\u201356.","journal-title":"Eur Urol"},{"issue":"5","key":"625_CR7","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195\u2013203.","journal-title":"J Urol"},{"issue":"3","key":"625_CR8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","volume":"58","author":"BW Rhijn Van","year":"2010","unstructured":"Van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433\u201341.","journal-title":"Eur Urol"},{"issue":"3","key":"625_CR9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","volume":"60","author":"J Fernandez-Gomez","year":"2011","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Club Urol\u00f3gico Espa\u00f1ol de Tratamiento Oncol\u00f3gico, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423\u201330.","journal-title":"Eur Urol"},{"issue":"3 Pt 1","key":"625_CR10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","volume":"164","author":"E Solsona","year":"2000","unstructured":"Solsona E, Iborra I, Dumont R, et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol. 2000;164(3 Pt 1):685\u20139.","journal-title":"J Urol"},{"issue":"4","key":"625_CR11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0090-4295(99)80047-8","volume":"45","author":"RJ Gils-Gielen Van","year":"1995","unstructured":"Van Gils-Gielen RJ, Witjes WP, Caris CT, et al. Risk factors in carcinoma in situ of the urinary bladder. Urology. 1995;45(4):581\u20136.","journal-title":"Urology"},{"issue":"3","key":"625_CR12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2014.11.031","volume":"67","author":"AH Mostafid","year":"2015","unstructured":"Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA. Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Gu\u00e9rin. Eur Urol. 2015;67(3):359\u201360.","journal-title":"Eur Urol"},{"issue":"2","key":"625_CR13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.juro.2011.10.032","volume":"187","author":"HW Herr","year":"2012","unstructured":"Herr HW. Intravesical bacillus Calmette-Gu\u00e9rin outcomes in patients with bladder cancer and asymptomatic bacteriuria. J Urol. 2012;187(2):435\u20137.","journal-title":"J Urol"},{"issue":"4","key":"625_CR14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","volume":"66","author":"CA Rentsch","year":"2014","unstructured":"Rentsch CA, Birkh\u00e4user FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, et al. Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. 2014;66(4):677\u201388.","journal-title":"Eur Urol"},{"issue":"4","key":"625_CR15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","volume":"93","author":"MD Shelley","year":"2004","unstructured":"Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485\u201390.","journal-title":"BJU Int"},{"issue":"6","key":"625_CR16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han RF, Pan JG. Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216\u201323.","journal-title":"Urology"},{"issue":"1","key":"625_CR17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90\u20135.","journal-title":"J Urol"},{"issue":"5","key":"625_CR18","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964\u201370.","journal-title":"J Urol"},{"key":"625_CR19","volume":"5","author":"PF Shang","year":"2011","unstructured":"Shang PF, Kwong J, Wang ZP, et al. Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2011;5, CD006885.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"625_CR20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"R J\u00e4rvinen","year":"2009","unstructured":"J\u00e4rvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009;56(2):260\u20135.","journal-title":"Eur Urol"},{"issue":"4","key":"625_CR21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R, Shariat S, Shariat SF, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. European Association of Urology. Eur Urol. 2013;64(4):639\u201353.","journal-title":"Eur Urol"},{"issue":"4","key":"625_CR22","first-page":"298","volume":"46","author":"A Astram","year":"2014","unstructured":"Astram A, Khadijah A, Yuri P, Zulfan A, et al. Effective dose and adverse effects of maintenance Bacillus Calmette-Guerin in intermediate and high risk non-muscle invasive bladder cancer: a meta-analysis of randomized clinical trial. Acta Med Indones. 2014;46(4):298\u2013307.","journal-title":"Acta Med Indones"},{"issue":"2","key":"625_CR23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180\u20133.","journal-title":"J Urol"},{"issue":"4","key":"625_CR24","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","volume":"161","author":"PU Malmstr\u00f6m","year":"1999","unstructured":"Malmstr\u00f6m PU, Wijkstr\u00f6m H, Lundholm C, Wester K, Busch C, Norl\u00e9n BJ. 5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161(4):1124\u20137.","journal-title":"J Urol"},{"key":"625_CR25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstrom","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette\u2013Guerin for non-muscle invasive bladder cancer. Eur Urol. 2009;56:247\u201325.","journal-title":"Eur Urol"},{"key":"625_CR26","first-page":"875","volume":"57","author":"SM Stasi Di","year":"1997","unstructured":"Di Stasi SM, Vespasiani G, Giannantoni A, et al. Electromotive delivery of mitomycin C into human bladder wall. Cancer Res. 1997;57:875\u201380.","journal-title":"Cancer Res"},{"key":"625_CR27","first-page":"3,849","volume":"51","author":"TD Schmittgen","year":"1991","unstructured":"Schmittgen TD, Wientjes MG, Badalament RA, Au JL. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res. 1991;51:3,849\u201356.","journal-title":"Cancer Res"},{"issue":"3","key":"625_CR28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"SM Stasi Di","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777\u201382.","journal-title":"J Urol"},{"issue":"1","key":"625_CR29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"SM Stasi Di","year":"2006","unstructured":"Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7(1):43\u201351.","journal-title":"Lancet Oncol"},{"issue":"6","key":"625_CR30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0090-4295(87)90429-8","volume":"15","author":"O Khanna","year":"1997","unstructured":"Khanna O, Cottone R, Son DL, et al. Superficial bladder cancer treated by intravesical bacillus Calmette\u2013Guerin or Adriamycin: multicenter study interim report. Urology. 1997;15(6):520\u20138.","journal-title":"Urology"},{"key":"625_CR31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462\u201372.","journal-title":"Eur Urol"},{"key":"625_CR32","doi-asserted-by":"crossref","unstructured":"Shelley MD, Mason MD. Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev. 2010;36:3.","DOI":"10.1016\/j.ctrv.2009.12.005"},{"issue":"1","key":"625_CR33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000471653","volume":"20","author":"E Rintala","year":"1991","unstructured":"Rintala E, Jauhiainen K, Alfthan O, Hansson E, et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Gu\u00e9rin) in superficial bladder cancer. Eur Urol. 1991;20(1):19\u201325.","journal-title":"Eur Urol"},{"issue":"3","key":"625_CR34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","volume":"1","author":"DL Lamm","year":"1995","unstructured":"Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith Jr JA, et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol. 1995;1(3):119\u201326.","journal-title":"Urol Oncol"},{"issue":"4","key":"625_CR35","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","volume":"173","author":"AG Heijden Van Der","year":"2005","unstructured":"Van Der Heijden AG, Verhaegh G, Jansen CFJ, Schalken JA, Witjes JA. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 2005;173(4):1375\u201380.","journal-title":"J Urol"},{"issue":"1","key":"625_CR36","first-page":"56","volume":"30","author":"YP Istomin","year":"2008","unstructured":"Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, Petrovich SV. Dose enhancement effect of anticancer drugs associated with increased temperature in vitro. Exp Oncol. 2008;30(1):56\u20139.","journal-title":"Exp Oncol"},{"issue":"3","key":"625_CR37","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-5347(01)67613-4","volume":"153","author":"R Colombo","year":"1995","unstructured":"Colombo R, Lev A, Da Pozzo LF, Freschi M, Gallus G, Rigatti P. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol. 1995;153(3):959\u201363.","journal-title":"J Urol"},{"issue":"2","key":"625_CR38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.radonc.2009.09.018","volume":"93","author":"M Wittlinger","year":"2009","unstructured":"Wittlinger M, R\u00f6del CM, Weiss C, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol. 2009;93(2):358\u201363.","journal-title":"Radiother Oncol"},{"issue":"7","key":"625_CR39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/02656730903213374","volume":"25","author":"J Crezee","year":"2009","unstructured":"Crezee J, Van Haaren PMA, Westendorp H, et al. Improving locoregional hyperthermia delivery using the 3-D controlled AMC-8 phased array hyperthermia system: a preclinical study. Int J Hyperth. 2009;25(7):581\u201392.","journal-title":"Int J Hyperth"},{"issue":"3","key":"625_CR40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3109\/02656739009140965","volume":"6","author":"GK Ogilvie","year":"1990","unstructured":"Ogilvie GK, Reynolds HA, Richardson BC, Badger CW, Goss SA, Burdette EC. Performance of a multi-sector ultrasound hyperthermia applicator and control system: in vivo studies. Int J Hyperth. 1990;6(3):697\u2013705.","journal-title":"Int J Hyperth"},{"issue":"1","key":"625_CR41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","volume":"60","author":"RJM Lammers","year":"2011","unstructured":"Lammers RJM, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60(1):81\u201393.","journal-title":"Eur Urol"},{"issue":"6","key":"625_CR42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","volume":"107","author":"R Colombo","year":"2011","unstructured":"Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107(6):912\u20138.","journal-title":"BJU Int"},{"issue":"3","key":"625_CR43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","volume":"27","author":"J Alfred Witjes","year":"2009","unstructured":"Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009;27(3):319\u201324.","journal-title":"World J Urol"},{"key":"625_CR44","doi-asserted-by":"crossref","first-page":"1,183","DOI":"10.1016\/j.eururo.2006.08.025","volume":"50","author":"A Giannantoni","year":"2006","unstructured":"Giannantoni A, Di Stasi SM, Chancellor MB, et al. New frontiers in intravesical therapies and drug delivery. Eur Urol. 2006;50:1,183\u201393.","journal-title":"Eur Urol"},{"key":"625_CR45","first-page":"4,912","volume":"59","author":"SM Stasi Di","year":"1999","unstructured":"Di Stasi SM, Giannantoni A, Massoud R, et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res. 1999;59:4,912\u20138.","journal-title":"Cancer Res"},{"key":"625_CR46","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","volume":"17","author":"DL Lamm","year":"1991","unstructured":"Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette\u2013Gu\u00e9rin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;17:1205\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"625_CR47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","volume":"143","author":"J Martinez-Pineiro","year":"1990","unstructured":"Martinez-Pineiro J, Jimenez Leon AJ, Martinez-Pineiro Jr L, et al. Bacillus Calmette\u2013Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990;143(3):502\u20136.","journal-title":"J Urol"},{"key":"625_CR48","volume":"1","author":"G Jones","year":"2012","unstructured":"Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012;1, CD009294.","journal-title":"Cochrane Database Syst Rev"},{"key":"625_CR49","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","volume":"62","author":"DR Yates","year":"2012","unstructured":"Yates DR, Brausi MA, Catto JW, et al. Treatment options available for bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer. Eur Urol. 2012;62:1088.","journal-title":"Eur Urol"},{"key":"625_CR50","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0022-5347(05)00423-4","volume":"175","author":"AM Kamat","year":"2006","unstructured":"Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006;175:881.","journal-title":"J Urol"},{"issue":"1","key":"625_CR51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eursup.2010.01.004","volume":"9","author":"E Juergen","year":"2010","unstructured":"Juergen E, Gschwend, Retz M, Kuebler H, Autenrieth M. Indications and oncologic outcome of radical cystectomy for urothelial bladder cancer. Eur Urol Suppl. 2010;9(1):10\u20138.","journal-title":"Eur Urol Suppl"},{"key":"625_CR52","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666\u201375.","journal-title":"J Clin Oncol"},{"key":"625_CR53","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166:1296\u20139.","journal-title":"J Urol"},{"key":"625_CR54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","volume":"100","author":"EH Lambert","year":"2007","unstructured":"Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007;100:33\u20136.","journal-title":"BJU Int"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-016-0625-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-016-0625-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-016-0625-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T04:23:23Z","timestamp":1568262203000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-016-0625-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1007\/s11934-016-0625-z","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]},"article-number":"68"}}